As millions of Americans ring in the New Year with renewed commitments to self-improvement, new study data from DeMayo Law Offices reveals a dramatic shift in how the country approaches weight loss. While roughly 30% of U.S. adults aged 18 and over make New Year’s resolutions annually, nearly half (49%) of those resolution-setters are between the ages of 18 and 29. Adults aged 30–49 account for 31%, while 21% of adults over 50 also commit to personal improvement goals. Among all resolutions, health dominates, and more than one-third of Americans who set goals aim specifically to lose weight.
But in 2025, weight loss is no longer defined solely by gym memberships and calorie counting. Instead, GLP-1 medications such as Ozempic and Wegovy have emerged as a powerful and increasingly mainstream tool for Americans looking to shed pounds.
Health Resolutions Dominate the New Year
Each January, millions of Americans pledge to live healthier, more balanced lives. Study data shows that 79% of resolution-makers focus on improving their overall health. Nearly half prioritize boosting fitness, while over one-third seek to improve mental well-being. Healthy eating remains a top objective, with about one-third of Americans committing to more nutritious diets.
Weight loss continues to rank among the most common goals. Beyond aesthetics, Americans cite improved mobility, better long-term health outcomes, and increased energy as key motivations. Rather than pursuing short-term fads, many individuals are seeking sustainable and science-backed approaches to wellness — a shift that is helping to fuel interest in prescription weight-loss medications.
GLP-1 Medications Move Into the Mainstream
GLP-1 drugs, originally developed to manage type 2 diabetes, work by regulating blood sugar, slowing digestion, and reducing appetite. Today, approximately 1 in 8 Americans (12%) report having tried a GLP-1 medication for weight loss.
Search data from January through October 2025 underscores the cultural momentum behind these drugs. Ozempic generated more than one million average monthly searches during that period, with interest surging sharply in January — coinciding with resolution season — and remaining elevated throughout the year. Searches for “GLP-1” climbed steadily, surpassing 800,000 monthly searches by late summer, signaling growing familiarity beyond brand names.
By comparison, general “weight loss” searches followed a predictable seasonal spike in January and March before tapering off significantly later in the year. In contrast, GLP-1 search activity remained consistently high, suggesting a long-term behavioral shift toward pharmaceutical solutions rather than short-lived dieting trends.
Prescription trends reinforce this pattern. Among adults aged 18–39, GLP-1 prescriptions increased nearly 588% between 2019 and 2024, according to the national health claims analysis. Adults aged 50–64 currently show the highest active usage rates at 22%, while 9% of adults aged 65 and older use GLP-1s, often limited by insurance coverage and eligibility restrictions. Meanwhile, younger adults represent the fastest-growing demographic, with 7% of those aged 18–29 and 6% of adults aged 30–49 reporting use specifically for weight loss.
Why Demand Is Rising
The popularity of GLP-1 medications reflects a broader shift in how Americans view obesity and chronic disease. With 42% of U.S. adults meeting clinical criteria for obesity, demand for effective and sustainable interventions continues to grow. Clinical trials published in leading medical journals demonstrate significant average weight loss among patients taking semaglutide and related drugs, helping propel GLP-1s from niche diabetes treatments into mainstream wellness tools.
Cultural visibility has amplified this momentum. Social media discussions, influencer testimonials, and celebrity endorsements have normalized prescription weight loss in previously uncommon ways. At the same time, telehealth expansion has made it easier than ever for patients to consult providers and obtain prescriptions.
Importantly, public attitudes toward obesity are evolving. Increasingly, weight management is viewed as a medical issue rather than a moral failing, contributing to reduced stigma around pharmaceutical treatment.
Costs and Coverage Remain Major Barriers
Despite surging interest, affordability remains a significant obstacle. Historically, GLP-1 medications have cost up to $1,000 per month without insurance. Recent manufacturer discounts have reduced some out-of-pocket costs to approximately $349 per month, but even this price point remains prohibitive for many.
Insurance coverage varies widely. While most plans cover GLP-1 drugs for diabetes management, many exclude coverage for weight loss unless strict criteria are met, including BMI thresholds and prior authorization requirements. Employers facing rising healthcare expenditures are also reevaluating long-term coverage strategies.
As a result, access remains uneven, often favoring individuals with comprehensive employer-sponsored insurance or higher disposable incomes. This affordability divide reinforces broader disparities in obesity treatment and chronic disease prevention.
Geographic Hotspots of Interest
Search data adjusted for population reveals that interest in GLP-1 medications spans every region of the country. Virginia leads the nation with approximately 934 searches per 100,000 residents. Illinois and North Carolina follow closely, each generating more than 850 searches per 100,000 residents.
Even highly populated states such as California, New York, and Texas show strong per-capita engagement, underscoring nationwide curiosity and sustained demand. Additional high-interest states include Georgia, Florida, Pennsylvania, and Ohio, illustrating that GLP-1 adoption is not limited to coastal markets but reflects a broad cultural shift.
Side Effects and Ongoing Monitoring
While GLP-1 medications are highly effective for many patients, side effects remain an important consideration. Gastrointestinal symptoms are most common, with nausea affecting nearly half of users. Vomiting, abdominal discomfort, acid reflux, and dehydration are also reported, particularly during early treatment stages or dosage increases.
Rare but serious risks include pancreatitis, gallbladder complications, and hypoglycemia when combined with other diabetes medications. Regulatory agencies continue monitoring reports related to mood changes; however, current large-scale research has not found a causal link between GLP-1 use and increased depression or suicidal ideation.
Beyond Weight Loss: Broader Health Benefits
Emerging research suggests GLP-1 medications may deliver benefits beyond weight reduction. A major cardiovascular trial found a 20% reduction in major cardiovascular events among overweight or obese adults with existing heart disease. Additional studies indicate improvements in blood pressure, blood sugar control, inflammation markers, and fatty liver disease risk.
These findings position GLP-1 medications not just as cosmetic weight-loss aids, but as potentially transformative tools in preventive medicine.
The Future of Resolution Season
As Americans head into a new year focused on health, the data shows that GLP-1 medications are reshaping the wellness landscape. With sustained search interest, rapid prescription growth, and expanding clinical validation, pharmaceutical weight management has become embedded in mainstream culture.
However, access disparities and safety considerations remain part of the conversation. As demand continues to rise, policymakers, insurers, employers, and healthcare providers will play a central role in determining whether these medications become a widely accessible public health solution — or remain an option available primarily to those who can afford it.
One thing is clear: in today’s resolution season, weight loss is no longer just about willpower. For millions of Americans, it’s increasingly about medicine.
